Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis

Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy.

[1]  D. Sachar,et al.  Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease , 2017, British Medical Journal.

[2]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[3]  A. Amiot,et al.  One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study , 2017, Alimentary pharmacology & therapeutics.

[4]  Jesus Romero,et al.  Integrated, reliable and cloud-based personal health record: A scoping review , 2016, ArXiv.

[5]  S. Saini,et al.  Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[6]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[7]  L. Peyrin-Biroulet,et al.  JAK inhibition in inflammatory bowel disease , 2017, Expert review of clinical immunology.

[8]  S. Saini,et al.  Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.

[9]  J. Hampe,et al.  Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study , 2016, Alimentary pharmacology & therapeutics.

[10]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[11]  G. Fiorino,et al.  IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy , 2017, Expert review of clinical immunology.

[12]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, American Journal of Gastroenterology.